Mobile-health Network Solutions Class A Ordinary Shares (MNDR) vs Virax Biolabs Group Limited (VRAX)

A side-by-side comparison of Mobile-health Network Solutions Class A Ordinary Shares and Virax Biolabs Group Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Mobile-health Network Solutions Class A Ordinary Shares logo
MNDR
Mobile-health Network Solutions Class A Ordinary Shares
$30054
$1.22HealthcareDelayed quote: Oct 6, 2026, 3:59 PM EDT
Virax Biolabs Group Limited logo
VRAX
Virax Biolabs Group Limited
$378849
$2.03HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — MNDR vs VRAX

growth of $100 · dividends reinvested · last 2y
MNDR -100.0% (-98.8%/yr)VRAX -87.7% (-64.9%/yr)VRAX compounded faster over this window
Log scale — wide-divergence pair
001101001kStart $10020252026$0$12
MNDR VRAX

MNDR vs VRAX: by the numbers

  • •VRAX is the larger company ($378849 vs $30054 market cap).
  • •Both run net losses; MNDR's is the smaller (-44.25% vs -40439.10% net margin).

Metrics side by side

Valuation

MetricMNDRVRAX
P/B ratio0.000.05

Profitability

MetricMNDRVRAX
Gross margin-11.45%61.90%
Operating margin-46.36%-51515.17%
Net margin-44.25%-40439.10%
ROE-124.31%-66.30%
ROIC-116.42%-83.46%

Growth (annualized)

MetricMNDRVRAX
Revenue CAGR (5Y)N/A-36.87%

Go deeper

Full MNDR analysisFull VRAX analysisInteractive comparison tool

Dig into the metrics

Mobile-health Network Solutions Class A Ordinary Shares ROEVirax Biolabs ROEMobile-health Network Solutions Class A Ordinary Shares operating marginVirax Biolabs operating marginMobile-health Network Solutions Class A Ordinary Shares revenue growthVirax Biolabs revenue growthMobile-health Network Solutions Class A Ordinary Shares free cash flowVirax Biolabs free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.